Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Mar 3;120(5):762-764.
doi: 10.1161/CIRCRESAHA.117.310452.

Pas de Deux: Glucagon and Thyroid Hormone Moving in Perfect Synchrony

Alexandra L Ghaben  1 , Philipp E Scherer  2
Affiliations
Comment

Pas de Deux: Glucagon and Thyroid Hormone Moving in Perfect Synchrony

Alexandra L Ghaben et al. Circ Res. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. Systemic effects of the Glucagon/T3 Hybrid Molecule
A novel method to unlock both the beneficial anti-lipid effects of glucagon and the energy expending effects of thyroid hormone by chemically conjugating the two entities. The molecule is thought to act primarily in the liver and in adipocytes, with glucagon acting as the primary component to deliver the T3 to liver and adipose tissue. This hybrid moiety bypasses many of the established side effects of the individual molecules and has potent glucose lowering and anti-lipidemic effects. PKA: Protein Kinase A activation; The Glucagon/T3 hybrid gets intracellularly cleaved in lysosomes (circular structures).
See this image and copyright information in PMC

Comment on

  • Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease.
    Finan B, Clemmensen C, Zhu Z, Stemmer K, Gauthier K, Müller L, De Angelis M, Moreth K, Neff F, Perez-Tilve D, Fischer K, Lutter D, Sánchez-Garrido MA, Liu P, Tuckermann J, Malehmir M, Healy ME, Weber A, Heikenwalder M, Jastroch M, Kleinert M, Jall S, Brandt S, Flamant F, Schramm KW, Biebermann H, Döring Y, Weber C, Habegger KM, Keuper M, Gelfanov V, Liu F, Köhrle J, Rozman J, Fuchs H, Gailus-Durner V, Hrabě de Angelis M, Hofmann SM, Yang B, Tschöp MH, DiMarchi R, Müller TD. Finan B, et al. Cell. 2016 Oct 20;167(3):843-857.e14. doi: 10.1016/j.cell.2016.09.014. Epub 2016 Oct 6. Cell. 2016. PMID: 27720451

References

    1. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. The American Journal of Medicine. 119:812–819. - PubMed
    1. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. New England Journal of Medicine. 1990;322:1700–1707. - PubMed
    1. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: A roadmap to lipotoxicity. Trends in endocrinology and metabolism: TEM. 2010;21:345–352. - PMC - PubMed
    1. Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vascular Health and Risk Management. 2008;4:341–353. - PMC - PubMed
    1. Finan B, Clemmensen C, Zhu Z, Stemmer K, Gauthier K, Müller L, De Angelis M, Moreth K, Neff F, Perez-Tilve D, Fischer K, Lutter D, Sánchez-Garrido Miguel A, Liu P, Tuckermann J, Malehmir M, Healy Marc E, Weber A, Heikenwalder M, Jastroch M, Kleinert M, Jall S, Brandt S, Flamant F, Schramm K-W, Biebermann H, Döring Y, Weber C, Habegger Kirk M, Keuper M, Gelfanov V, Liu F, Köhrle J, Rozman J, Fuchs H, Gailus-Durner V, Hrabě de Angelis M, Hofmann Susanna M, Yang B, Tschöp Matthias H, DiMarchi R, Müller Timo D. Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease. Cell. 167:843–857. e814. - PubMed

Publication types